205 related articles for article (PubMed ID: 23484132)
1. A potential therapeutic strategy for malignant mesothelioma with gene medicine.
Tada Y; Shimada H; Hiroshima K; Tagawa M
Biomed Res Int; 2013; 2013():572609. PubMed ID: 23484132
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for malignant mesothelioma: current prospects and challenges.
Tagawa M; Tada Y; Shimada H; Hiroshima K
Cancer Gene Ther; 2013 Mar; 20(3):150-6. PubMed ID: 23392201
[TBL] [Abstract][Full Text] [Related]
3. Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.
Sterman DH; Alley E; Stevenson JP; Friedberg J; Metzger S; Recio A; Moon EK; Haas AR; Vachani A; Katz SI; Sun J; Heitjan DF; Hwang WT; Litzky L; Yearley JH; Tan KS; Papasavvas E; Kennedy P; Montaner LJ; Cengel KA; Simone CB; Culligan M; Langer CJ; Albelda SM
Clin Cancer Res; 2016 Aug; 22(15):3791-800. PubMed ID: 26968202
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
Harada A; Uchino J; Harada T; Nakagaki N; Hisasue J; Fujita M; Takayama K
Cancer Sci; 2017 Jan; 108(1):116-123. PubMed ID: 27783867
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy.
Deng XB; Xiao L; Wu Y; Jin F; Mossman B; Testa JR; Xiao GH
Int J Cancer; 2015 Jul; 137(2):481-90. PubMed ID: 25501304
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for malignant pleural mesothelioma: present and future.
Tada Y; Takiguchi Y; Hiroshima K; Shimada H; Ueyama T; Nakamura M; Tatsumi K; Kuriyama T; Tagawa M
Oncol Res; 2008; 17(6):239-46. PubMed ID: 19192718
[TBL] [Abstract][Full Text] [Related]
7. Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model.
Keshava S; Rao LV; Pendurthi UR
Sci Rep; 2016 Nov; 6():36829. PubMed ID: 27833109
[TBL] [Abstract][Full Text] [Related]
8. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
Bononi A; Napolitano A; Pass HI; Yang H; Carbone M
Expert Rev Respir Med; 2015 Oct; 9(5):633-54. PubMed ID: 26308799
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.
Nuvoli B; Galati R
Mol Cancer Ther; 2013 Jun; 12(6):844-52. PubMed ID: 23729401
[TBL] [Abstract][Full Text] [Related]
10. [Molecular heterogeneity of malignant pleural mesotheliomas].
Tranchant R; Montagne F; Jaurand MC; Jean D
Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
[TBL] [Abstract][Full Text] [Related]
11. Advances in systemic therapy for malignant mesothelioma: future perspectives.
Sobhani N; Corona SP; Bonazza D; Ianza A; Pivetta T; Roviello G; Cortale M; Guglielmi A; Zanconati F; Generali D
Future Oncol; 2017 Oct; 13(23):2083-2101. PubMed ID: 28984470
[TBL] [Abstract][Full Text] [Related]
12. Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.
Murthy V; Katzman D; Sterman DH
Clin Respir J; 2019 May; 13(5):272-279. PubMed ID: 30810270
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for lung neoplasms.
Vachani A; Moon E; Wakeam E; Haas AR; Sterman DH; Albelda SM
Clin Chest Med; 2011 Dec; 32(4):865-85. PubMed ID: 22054892
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.
Kuryk L; Haavisto E; Garofalo M; Capasso C; Hirvinen M; Pesonen S; Ranki T; Vassilev L; Cerullo V
Int J Cancer; 2016 Oct; 139(8):1883-93. PubMed ID: 27287512
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma.
Sterman DH; Molnar-Kimber K; Iyengar T; Chang M; Lanuti M; Amin KM; Pierce BK; Kang E; Treat J; Recio A; Litzky L; Wilson JM; Kaiser LR; Albelda SM
Cancer Gene Ther; 2000 Dec; 7(12):1511-8. PubMed ID: 11228529
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
[TBL] [Abstract][Full Text] [Related]
17. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
Chirac P; Maillet D; Leprêtre F; Isaac S; Glehen O; Figeac M; Villeneuve L; Péron J; Gibson F; Galateau-Sallé F; Gilly FN; Brevet M
Hum Pathol; 2016 Sep; 55():72-82. PubMed ID: 27184482
[TBL] [Abstract][Full Text] [Related]
18. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
Watanabe Y; Kojima T; Kagawa S; Uno F; Hashimoto Y; Kyo S; Mizuguchi H; Tanaka N; Kawamura H; Ichimaru D; Urata Y; Fujiwara T
Oncogene; 2010 Feb; 29(8):1145-54. PubMed ID: 19935710
[TBL] [Abstract][Full Text] [Related]
19. Malignant mesothelioma: development to therapy.
Thompson JK; Westbom CM; Shukla A
J Cell Biochem; 2014 Jan; 115(1):1-7. PubMed ID: 23959774
[TBL] [Abstract][Full Text] [Related]
20. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma.
Smythe WR; Kaiser LR; Hwang HC; Amin KM; Pilewski JM; Eck SJ; Wilson JM; Albelda SM
Ann Thorac Surg; 1994 Jun; 57(6):1395-401. PubMed ID: 8010779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
